Format Therapeutics Provides 2021 Priorities
Format Therapeutics Provides 2021 Priorities
Strong pipeline progress in 2020 positions company well for 2021
Established proof of concept in SCD for FT-4202
Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML
Enrolling Phase 1 FT-7051 trial for prostate cancer - including patient with AR-v7 splice variants
Completed successful IPO and follow-on equity offering
Strong pipeline progress in 2020 positions company well for 2021
2020年管道的強勁進展為公司2021年做好了準備
Established proof of concept in SCD for FT-4202
已確定FT-4202在SCD中的概念證明
Potential transformative treatment profile for IDH1 inhibitor olutasidenib in R/R/ AML
IDH1抑制劑olutasidenib在R/R/AML中的潛在轉化性治療概況
Enrolling Phase 1 FT-7051 trial for prostate cancer - including patient with AR-v7 splice variants
為前列腺癌招募1期FT-7051試驗--包括攜帶AR-v7剪接變異的患者
Completed successful IPO and follow-on equity offering
成功完成首次公開募股(IPO)和後續配股
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧